Telaprevir/boceprevir era: From bench to bed and back

Qiuwei Pan, Maikel P Peppelenbosch, Harry LA Janssen, Robert J de Knegt

Qiuwei Pan, Maikel P Peppelenbosch, Harry LA Janssen, Robert J de Knegt, Department of Gastroenterology and Hepatology, Erasmus MC-University Medical Center, 3015 CE Rotterdam, The Netherlands

Author contributions: Pan Q contributed to conception, design, drafting the article and acquisition, interpretation of the data; Peppelenbosch MP, Janssen HLA and de Knegt RJ contributed to interpretation of data and editing the article; all the authors revised and approval of the version to be published.

Support by: Foundation for Liver and Gastrointestinal Research (SLO); and The Netherlands Organisation for Scientific Research (NWO), No. VENI-grant 916-13-032 (to Pan Q)

Correspondence to: Qiuwei Pan, PhD, Department of Gastroenterology and Hepatology, Erasmus MC-University Medical Center, Room L-462, ’s Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands. q.pan@erasmusmc.nl

Telephone: +31-10-7034545 Fax: +31-10-7032793

Received: August 6, 2012 Revised: September 25, 2012 Accepted: September 28, 2012 Published online: November 21, 2012

Abstract

Hepatitis C virus (HCV) infects approximately 200 million people worldwide. Interferon-based therapies have dominated over the past two decades. However, the overall response rates remain suboptimal. Thanks to the tremendous effort from both academia and industry, two serine protease inhibitors telaprevir and boceprevir for treating chronic hepatitis C have finally reached the clinic. Although these compounds are only approved for combination use with interferon and ribavirin in genotype 1 HCV infected chronic patients, the management of HCV patients however is now evolving incredibly. Here, we overviewed a series of landmark studies, regarding the clinical development of telaprevir and boceprevir. We discussed the mechanism-of-action of telaprevir/boceprevir and their potential application in HCV-positive liver transplantation patients. We further emphasized some emerging concerns with perspective of further development in this field.

Key words: Telaprevir; Boceprevir; Mechanism-of-action; Clinical efficacy; Liver transplantation patient; Interferon; Ribavirin

Peer reviewers: Dr. Dahlene N Fusco, Gastrointestinal Unit, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, United States; Akihito Tsunoda, MD, Department of Gastroenterology, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, Tokyo 105-8470, Japan

Pan Q, Peppelenbosch MP, Janssen HLA, de Knegt RJ. Telaprevir/boceprevir era: From bench to bed and back. World J Gastroenterol 2012; 18(43): 6183-6188 Available from: URL: http://www.wjgnet.com/1007-9327/full/v18/i43/6183.htm DOI: http://dx.doi.org/10.3748/wjg.v18.i43.6183

INVITED COMMENTARY ON HOT ARTICLES

Since the discovery of hepatitis C virus (HCV) in 1989[1], the lack of good model systems has hampered the research at the early stages. Even though still little is known about the virus, interferon was found to be effective for treating chronic HCV and the first interferon-α (IFN-α) is approved by the United States Food and Drug Administration (FDA) to treat HCV in 1991[2]. Interferons have a vital role for immune modulation of the host cells and involve the induction of a multitude of interferon-stimulated genes to establish an antiviral status[3]. Through a series of optimizations, the current pegylated interferon (peg-IFN) in combination with ribavirin has dramatically improved the outcome, but still only approximately 50% of the patients can develop a sustained virologic response (SVR)[4,5].

Thanks to the development of various cell culture models and the important evolvement of biotechnology[6], research in the HCV field has been flourishing both in academia and industry, over the past decade. This progress has enabled further improvement on the current interferon-based standard antiviral therapy and
Mechanism-of-action of telaprevir and boceprevir

The HCV genome comprises of a single open reading frame, encoding a polyprotein precursor of approximately 3000 amino acids, flanked by 5' and 3' non-coding region (NCR). Translation of the viral polyprotein is mediated by an internal ribosome entry site located within the highly conserved 5' NCR. The synthesized polyprotein is subsequently cleaved into four structural (core, E1, E2 and p7) and six non-structural (NS2, NS3, NS4A, NS4B, NS5A and NS5B) proteins[8]. Processing of structural proteins, including the p7/NS2 junction, is carried out by at least two host signal peptidases and non-structural proteins and is matured by two viral proteases, NS2 and NS3/4A[8,9].

The NS3/4A serine protease is a non-covalent, heterodimer complex formed by the catalytic subunit of the N-terminal serine protease domain of NS3 and the activation subunit of the NS4A cofactor. Unique to the NS3 protease is an extended polydentate substrate binding cleft, which ensures substrate specificity[10]. It is responsible for the proteolytic cleavage of NS3/NS4A self cleavage, NS4A/NS4B, NS4B/NS5A and NS5A/NS5B. The multi-functional property of NS3/4A protease has attracted for targeted drug development. Current protease inhibitors can be divided into covalent and non-covalent peptidomimetic inhibitors. Telaprevir and boceprevir are covalent linear inhibitors, discovered by using structure-based drug design approach[11,12]. Both act via formation of a reversible covalent interaction with serine-139. The assayment of electrophilic carbonyl of the ketoamide by the catalytic serine leads to tetrahedral formation which mimics the transition state of peptide bond cleavage. This is further stabilized by additional ionic interactions with the active site[11,12]. However, telaprevir and boceprevir were designed to target the protease of genotype 1 HCV and therefore their activity varies among genotypes. Experimental data has shown that both were active against genotypes 2, 5 and 6, but not 3[13]. Clinical evidence suggested that telaprevir was effective against genotype 2 but not genotype 3 and uncertain for genotype 4[1,4,5].

Clinical efficacy

Two weeks monotherapy with telaprevir has demonstrated substantial antiviral activity in patients with genotype 1 HCV in a phase 1 trial (3 log drop in viral load in majority of patients). However, some patients showed resistance to telaprevir can be seen from viral break-through during dosing and were associated with selection of the variants[10]. Therefore, combination therapy with peg-IFN-α/ribavirin was required for the subsequent larger multicentre phase 2, PROVE 1[17], PROVE 2[18] and PROVE 3[19] trials. Overall, telaprevir increased 20%-30% SVR rates in both naïve and genotype 1 treated patients (Figure 1). Ribavirin was an essential component of this triple therapy (Figure 1).

Phase 3 trials in the treatment of naïve or experienced patients were carried out in the ADVANCE[20] and REALIZE[21] studies, respectively. Superior SVR rates with treatment of telaprevir-based regimens were confirmed in both naïve and experienced genotype 1 patients. The illuminate phase 3 study supported the concept of response-guided telaprevir combination treatment (RGT) in naïve patients. This study summarized that treatment of telaprevir in combination with peg-IFN/ribavirin in the first 12 and 24 wk was noninferior to the same regimen for 48 wk in patients with undetectable HCV RNA at weeks 4 and 12[22].

One week monotherapy with boceprevir resulted in an average HCV RNA load reduction of about 1.0 and 1.6 log10 IU/mL in nonresponders of peg-IFN/ribavirin at dose of 200 mg and 400 mg, 3 times a day, respectively[23]. However, during boceprevir monotherapy, resistance mutations at six positions within the NS3 protease were detected. All mutations were associated with reduced replicative fitness estimated by mathematical modeling with cross-resistance to telaprevir[24]. Similarly, the successful clinical development of boceprevir treatment was used in combination with peg-IFN/ribavirin both in naïve and experienced genotype 1 patients, as demonstrated in the phase 2b SPRINT-1 trial (Figure 2)[25], the phase 3 SPRINT-2 trial (Figure 2)[26] and the phase 3 RESPOND-2 trial (Figure 2)[27].

The most serious adverse effects of telaprevir were rash and anemia and of boceprevir were anaemia, dysguesia, neutropenia and anal discomfort.

The use of DAAAs in liver transplant patients?

End-stage liver disease caused by chronic HCV infection is currently the leading indication for liver transplantation[28]. However, HCV re-infection of the graft occurs universally and often results in accelerated recurrence of liver fibrosis and early development of cirrhosis[29]. In general, peg-IFN/ribavirin is much less effective in transplant patients with approximate SVR rates of only 20%-35[30]. An aggravated course of infection and more resistance to antiviral therapy have been attributed to several host and viral factors, in particular the application of specific immunosuppressive medication[31].

The suppression of HCV viraemia in pre-transplant patients may attenuate the risk of viral recurrence. However, the tolerability and efficacy of peg-IFN/ribavirin antiviral therapy is compromised in decompensated cirrhosis patients[32]. For telaprevir or boceprevir, a few patients with advanced fibrosis or compensated cirrhosis have been included in these phase 3 trials[20,21,26,27]. However,
ever, the response rates in patients with advanced fibrosis were significantly lower than in patients with mild to moderate fibrosis but there is no experience in patients with decompensated cirrhosis so far.

Although prophylactic treatment, preemptive treatment or treatment of established HCV recurrence after transplantation with peg-IFN/ribavirin is common, its tolerability and efficacy remain unsatisfactory. Therefore, there is much expectation of telaprevir and boceprevir for improving the outcome in liver transplant patients. In the 18th annual congress of the International Liver Transplantation Society this year in San Francisco, United States, the first series of clinical data of treating HCV recurrence using telaprevir or boceprevir in liver transplant patients were revealed, although these were rather small clinical studies. In a multicenter study of 7 patients, 2 patients had an undetectable viral load and 2 had viral load below 2 log at week 12 after treatment with boceprevir in combination with peg-IFN/ribavirin. However, all patients had severe anemia requiring erythropoietin and 4 patients required granulocyte colony stimulating factor. The dosage of peg-IFN and/or ribavirin was reduced in 4 patients and treatment was stopped prematurely in 3 patients. In one of the telaprevir-based triple therapy studies, 2 out of 9 patients achieved rapid viral response, however hematological ad-

---

**Figure 1** The outcome of the five landmark trials for telaprevir-based triple therapy in hepatitis C virus genotype 1 patients. Sustained virologic response rates are compared between groups. PROVE 1, PROVE 2 and ADVANCE trials were conducted in treatment-naïve patients. PROVE 3 and REALIZE trials were conducted in treatment-experienced patients. T: Telaprevir; P: Peg-IFN; R: Ribavirin. The numbers (8, 12, 24 or 48): Week of treatment; SVR: Sustained virologic response.
Another 2 patients achieved 2-log and 3-log viral reduction of these 4 patients obtained SVR after 5 wk of therapy. Two out of 4 out of 5 patients were telaprevir tolerated but 1 patient stopped the treatment due to complications. verse events were common, including anemia and leukopenia. In another telaprevir-based triple therapy study, 4 out of 5 patients were telaprevir tolerated but 1 patient stopped the treatment due to complications. Two out of these 4 patients obtained SVR after 5 wk of therapy. Another 2 patients achieved 2-log and 3-log viral reduction in the 1st week follow-up, respectively. Triple combination therapy has shown substantial antiviral efficacy but larger properly designed trials are definitely required to further evaluate the use of telaprevir and boceprevir in this setting. However, these studies have consistently raised the concerns of poor tolerability of these compounds in transplant patients. Clinical studies of additional DAAs peri-transplant are in progress and should be monitored closely.

In addition to the adverse events, potential interactions between telaprevir/boceprevir with immunosuppressive drugs are other concerns. As reported in a phase 1 study, telaprevir interferes the metabolism of both cyclosporin A (CsA) and tacrolimus by inhibition of cytochrome P450 3A enzymatic activity. Telaprevir caused a significant increase in blood concentrations of both immunosuppressants and could potentially lead to serious or even life-threatening adverse effects. McCashland et al. has specifically evaluated the drug level profile of CsA during telaprevir therapy in liver transplant patients, however no negative impact in achieving CsA target levels was observed. In fact, different immunosuppressive drugs can also have distinct effects on peg-IFN/ribavirin, such as CsA and MPA can promote the antiviral effects of interferon whereas tacrolimus does not. Thus, more attention from both basic and clinical perspective is needed, regarding drug to drug interaction with telaprevir/boceprevir.

**The role of interferon and ribavirin?**

Monotherapy with telaprevir or boceprevir not only been associated with resistance but also the antiviral potency is not sufficient for complete eradication of the virus. Therefore, combination treatment with peg-IFN/ribavirin has emerged as the ultimate solution to resolve these limitations. A specific issue which would be concerned is that whether the IL28B genetic variation as one of the important SVR prediction factors to peg-IFN/ribavirin, is still relevant to telaprevir/boceprevir-based triple combination therapy or not. In treatment of naïve patients, the IL28B rs12979860-CC genotype was a positive predictor to select appropriate candidates for RGT in the ADVANCE and SPRINT-2 trials. In treatment of experienced patients, the CC genotype however is less frequent than in general population, IL28B therefore is expected to be less important for response prediction. However, data remain limited to address the exact prediction value of IL28B genotype in telaprevir/boceprevir-based triple combination therapy or not. Another clear evidence from the PROVE and SPRINT trials suggested that the treatment regimens with low-dose or without ribavirin were associated with lower SVR rates, probably due to viral breakthrough and viral relapse after therapy. An emerging concept is the development of interferon-free regimens, which aims to limit the contraindications and adverse effects of peg-IFN. The combination of different reagents offers the potential for interferon-
free therapy including the development of various DAs such as protease, NS4B, NS5A, polymerase inhibitors and host-targeting agents including cyclophilin inhibitors and anti-miR-122 oligonucleotides[46]. In current clinical trials, different DAA combinations with or without ribavirin are the main scenario. It is not surprising that with or without interferon, a study of combining a non-nucleoside polymerase inhibitor with a protease inhibitor clearly showed the benefit of ribavirin[31]. In spite of the mechanism of how ribavirin can synergize interferon that has been extensively extrapolated[42,43], the mechanism of how ribavirin works with DAs are poorly investigated. Notably, a recent study has shown that high SVR rate could be achieved with two DAs (the NS5A inhibitor daclatasvir and the NS3 inhibitor asunaprevir) only, although higher SVR rates were achieved when combined with peg-IFN/ribavirin[45]. Therefore, it remains an open question regarding the future of ribavirin in interferon-free-based DAA combination therapy. Further basic and clinical research will conceivably help to figure out this issue.

Summary and perspectives
The approval of telaprevir and boceprevir by FDA and the European Medicines Agency in last year (2011) has indeed changed the management of chronic HCV. From these series of clinical landmark studies, a 20%-30% increase of SVR rates were obtained with the additional telaprevir/boceprevir to the conventional standard peg-IFN/ribavirin therapy. Despite these exciting results, certainly there are several remaining concerns. An apparent limitation of telaprevir/boceprevir as well as most of the pipeline DDAs (such as protease inhibitors asunaprevir, BI 201335 and ABT-450) is genotype 1 specificity, whereas other HCV genotypes also prevail all over the world. Secondly, these compounds have very low genetic barrier to the development of resistant viral variants. Thirdly, although telaprevir/boceprevir are generally well tolerated, their adverse effects are still hampering the successful application in specific populations, particularly for liver transplant patients.

Perspectively, these issues could likely be minimized by further optimizing the clinical protocol. In addition, by the development of other compounds, more optimal combinations will be available. As being expected, the dream of achieving high SVR rates with all-oral interferon-free regimens will be no longer far from clinical reality.

REFERENCES
1 Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Isolation of a CDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989; 244: 359-362
2 Hess G. Treatment of chronic hepatitis C. J Hepatol 1991; 13 Suppl 1: S17-S20
3 Sun L, Liu S, Chen ZJ. SnapShot: pathways of antiviral innate immunity. Cell 2010; 140: 436-436.e2
4 Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 38: 645-652
5 Zeuzem S, Buti M, Ferenci P, Sperl J, Hoormans Y, Cianciara J, Brianyi E, Weiland O, Noviello S, Brass C, Albrecht J. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006; 44: 97-103
6 Boonstra A, van der Laan LJ, Vanvollehghem T, Janssen HL. Experimental models for hepatitis C viral infection. Hepatology 2009; 50: 1646-1655
7 Casey LC, Lee WM. Hepatitis C therapy update. Curr Opin Gastroenterol 2012; 28: 188-192
8 Penin F, Dubuisson J, Rey FA, Moradpour D, Pawlotsky JM. Structural biology of hepatitis C virus. Hepatology 2004; 39: 5-19
9 Bartenschlager R, Ahlborn-Laake L, Mous J, Jacobsen H. Kinetic and structural analyses of hepatitis C virus polyprotein processing. J Virol 1994; 68: 5045-5055
10 Berger A, Schechter I. Mapping the active site of papain with the aid of peptide substrates and inhibitors. Philos Trans R Soc Lond B Biol Sci 1970; 257: 249-264
11 Perni RB, Almajist SJ, Byrn RA, Chandorgar G, Chaturvedi PR, Courtney LF, Decker CJ, Dinehart K, Gates CA, Harbeson SL, Heiser A, Kalkfiet G, Kolaczkowski E, Lin K, Luong YP, Rao BC, Taylor WP, Thomson JA, Tung RD, Wei Y, Kwong AD, Lin C. Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease. Antimicrob Agents Chemother 2006; 50: 899-909
12 Malcolm BA, Liu R, Lahser F, Agrawal S, Belanger B, Butkiewicz N, Chase R, Gheyas R, Hart A, Hesk D, Ingravallo P, Jiang C, Kong R, Lu J, Pichardo J, Prongay A, Skelton A, Tong X, Venkatraman S, Xu F, Girish, Talabban V, Njorge FG, SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells. Antimicrob Agents Chemother 2006; 50: 1013-1020
13 Gottwein JM, Scheel TK, Jensen TB, Ghanein L, Bukh J. Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a, and 6a NS3/4A protease recombinant viruses. Gastroenterology 2011; 141: 1067-1077
14 Foster GR, Hézode C, Bronwick JP, Carosi G, Weiland O, Verlinden L, Van Heeswijk R, Van Baelen B, Picchio G, Beu mont M. Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections. Gastroenterology 2011; 141: 881-889.e1
15 Schaefer EA, Chung RT. Anti-hepatitis C virus drugs in development. Gastroenterology 2012; 142: 1340-1350.e1
16 Reesink HW, Zeuzem S, Weegink CJ, Forestier N, van Vliet A, van de Wetering de Rooij J, McNair L, Purdy S, Kauff man R, Alam J, Jansen PL. Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study. Gastroenterology 2006; 131: 997-1002
17 McHutchison JG, Eversen GT, Gordon SC, Jacobson JM, Sulkowski M, Kauffman R, McNair L, Alam J, Muir AJ. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360: 1827-1838
18 Hézode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goessler T, Bronwick JP, Bourlière M, Gharakhanian S, Bengtsson P, McNair L, George S, Kieffer T, Kwong A, Kauffmann RS, Alam J, Pawlotsky JM, Zeuzem S. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360: 1839-1850
19 McHutchison JG, Manns MP, Muir AJ, Terrault NA, Jacobson IM, Afdhal NH, Heathcote EJ, Zeuzem S, Reesink HW, Garg J, Bsharat M, George S, Kauffmann RS, Adda N, Di Bisceglie AM. Telaprevir for previously treated chronic
HCV infection. *N Engl J Med* 2010; 362: 1292-1303

20 Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Fliksik R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Benghsom L, Sankoh AJ, Kieffer TL, George S, Kaufman RS, Zeuzem S. Telaprevir for previously untreated chronic hepatitis C virus infection. *N Engl J Med* 2011; 364: 2405-2416

21 Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, Ferenci P, Nevens F, Mullhauff B, Pockros P, Terg R, Shouval D, van Hoek B, Weland O, Van Heeswijk R, De Meyer S, Luo D, Boogaerts G, Polo R, Picchio G, Beumont M. Telaprevir for retreatment of HCV infection. *N Engl J Med* 2011; 364: 2417-2428

22 Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, Fried MW, Adler M, Reesink HW, Martin M, Sankoh AJ, Adda N, Kaufman RS, George S, Wright CI, Poordad F. Response-guided telaprevir combination treatment for chronic hepatitis C virus infection. *N Engl J Med* 2011; 365: 1014-1024

23 Sarrazin C, Rouzier R, Wagner F, Forestier N, Larrey D, Gupta SK, Hussain M, Shah A, Cutler D, Zhang J, Zeuzem S. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon-alpha-2b for genotype 1 nonresponders. *Gastroenterology* 2007; 132: 1270-1278

24 Susser S, Welsch C, Wang Y, Zettel M, Domingues FS, Karrey U, Hughes E, Ralston R, Tong X, Herrmann E, Zeuzem S, Sarrazin C. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. *Hepatology* 2009; 50: 1709-1718

25 Kwo PY, Lawitz EJ, McConne J, Schiff ER, Vierling JM, Pond D, Davis MN, Galati JS, Gordon SC, Ravendranth N, Rossaro L, Anderson FH, Jacobson IM, Rubin R, Koury K, Pedicone LD, Brass CA, Chaudhuri E, Albrecht JK. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. *Lancet* 2010; 376: 705-716

26 Poordad F, McConne J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Smiukiene V, Brass CA, Albrecht JK, Bronowicki JP. Boceprevir for untreated chronic HCV genotype 1 infection. *N Engl J Med* 2011; 364: 1195-1206

27 Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, Goodman ZD, Sings HL, Boparai N, Burroughs M, Brass CA, Albrecht JK, Esteban R. Boceprevir for previously treated chronic HCV genotype 1 infection. *N Engl J Med* 2011; 364: 1207-1217

28 Brown BS. Hepatitis C and liver transplantation. *Nature* 2005; 436: 973-978

29 Yilmaz N, Shiffman ML, Stratvitz RT, Sterling RK, Luketic VA, Sanyal AJ, Mills AS, Contos MJ, Cotrell E, Maluf D, Posner MP, Fisher RA. A prospective evaluation of fibrosis progression in patients with recurrent hepatitis C virus following liver transplantation. *Liver Transpl* 2007; 13: 975-983

30 Samuel D, Bizollon T, Fayer C, Roche B, Ahmed SN, Lemmonier C, Cohard M, Reeves M, Chevallier M, Ducerf C, Baulieux J, Gefner M, Albrecht JK, Bismuth H, Trepo C. Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. *Gastroenterology* 2003; 124: 642-650

31 Pan Q, Tihanus HW, Metselaar HJ, Janssen HL, van der Laan LJ. Virus-drug interactions–molecular insight into immunosuppression and HCV. *Nat Rev Gastroenterol Hepatol* 2012; 9: 355-362

32 Bruno S, Shiffman ML, Roberts SK, Gane EJ, Messinger D, Hadziyannnis SJ, Marcellin P. Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis. *Hepatology* 2010; 51: 388-397

33 Bzowej N, Nelson DR, Terrault NA, Everson GT, Teng LL, Prabhakar A, Charlton MR. PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus. *Liver Transpl* 2011; 17: 528-538

34 Coilly A, Roche B, Botta-Fridlund D, Leroy V, Pageaux PG, Si-Ahmed SN, Antonini TM, Samuel D, Dulas-Vallee JC. A First Multicentric Experience of Protease Inhibitors for Severe Hepatitis C Recurrence after Liver Transplantation. *Liver Transpl* 2012; 18: S84-S85

35 McCashland TM, Olivera-Martinez MA, de Sicilia MGS, Mukherjee S, Roche B, Schafer DF, Sorrell MF. Early Experience with Triple Drug Therapy (Telaprevir, Pegylated Interferon alpha 2A and Ribavirin) in Patients on Cyclosporine A for Hepatitis C Recurrence after Liver Transplantation. *Liver Transpl* 2012; 18: S130

36 Shin HJ, Pereira AD, Safdar A, Tobias H, Gelb B, Morgan G, Diffo T, Teperman L. Initial Experience of Telaprevir for Recurrent Hepatitis C in Post Liver Transplant Patients. *Liver Transpl* 2012; 18: S130

37 Garg V, van Heeswijk R, Lee JE, Alves K, Nadkarni P, Luo X. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. *Hepatology* 2011; 54: 20-27

38 Pan Q, de Ruiter PE, Metselaar HJ, Kwekkeboom J, de Jonge J, Tihanus HW, Janssen HL, van der Laan LJ. Mycophenolic acid augments interferon-stimulated gene expression and inhibits hepatitis C Virus infection in vitro and in vivo. *Hepatology* 2012; 55: 1673-1683

39 Pan Q, Metselaar HJ, de Ruiter P, Kwekkeboom J, Tihanus HW, Janssen HL, van der Laan LJ. Calcineurin inhibitor tacrolimus does not interfere with the suppression of hepatitis C virus infection by interferon-alpha. *Liver Transpl* 2010; 16: 520-526

40 Welsch C, Jesudian A, Zeuzem S, Jacobson I. New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives. *Cyt 2012; 61 Suppl 1: 136-146

41 Zeuzem S, Buggisch P, Agarwal K, Marcellin P, Sereni D, Klinker H, Moreno C, Zarski JP, Horsmans Y, Mo H, Arterburn S, Knox S, Oldach D, McHutchison JG, Manns MP, Foster GR. The protease inhibitor GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C. *Hepatology* 2012; 55; 749-758

42 Thomas E, Feld JJ, Li Q, Hu Z, Fried MW, Liang TJ. Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models. *Hepatology* 2011; 53: 32-41

43 Pan Q, Tihanus HW, Janssen HL, van der Laan LJ. Ribavirin enhances interferon-stimulated gene transcription by activation of the interferon-stimulated response element. *Hepatology* 2011; 53: 1400-1401; author reply 1402

44 Thomas E, Ghany MG, Liang TJ. The application and mechanism of action of ribavirin in therapy of hepatitis C. *Antivir Chem Chemother* 2012; 23: 1-12

45 Lok AS, Gardiner DF, Lawitz E, Martorell C, Everson GT, Ghalib R, Reindollar R, Rustgi V, McPhee F, Wind-Rotolo M, Persson A, Zhu K, Dimitrova DJ, Eley T, Guo T, Gra-sela DM, Pasquilleni C. Preliminary study of two antiviral agents for hepatitis C genotype 1. *N Engl J Med* 2012; 366: 216-224